NEW YORK (GenomeWeb News) – Asuragen today announced it has granted Becton Dickinson the rights to incorporate its Armored RNA technology into BD's in vitro molecular diagnostic products.

Asuragen will develop and supply reagents for BD Diagnostics in Asuragen's cGMP manufacturing facility under the terms of the deal. Other details of the non-exclusive worldwide agreement were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.

Cancer clinical trial patients settle with Anil Potti and Duke University.

A trio of researchers is trying to raise money to sequence and analyze the genome of a cat with a suite of unusual traits.

Two Johns Hopkins researchers discuss the need for evidence-based data analysis.